146 related articles for article (PubMed ID: 23432687)
1. Cyclosporine modulation of multidrug resistance in combination with pravastatin, mitoxantrone and etoposide for adult patients with relapsed/refractory acute myeloid leukemia: a phase 1/2 study.
Chen TL; Estey EH; Othus M; Gardner KM; Markle LJ; Walter RB
Leuk Lymphoma; 2013 Nov; 54(11):2534-6. PubMed ID: 23432687
[No Abstract] [Full Text] [Related]
2. Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia.
Dahl GV; Lacayo NJ; Brophy N; Dunussi-Joannopoulos K; Weinstein HJ; Chang M; Sikic BI; Arceci RJ
J Clin Oncol; 2000 May; 18(9):1867-75. PubMed ID: 10784627
[TBL] [Abstract][Full Text] [Related]
3. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
Tallman MS; Lee S; Sikic BI; Paietta E; Wiernik PH; Bennett JM; Rowe JM
Cancer; 1999 Jan; 85(2):358-67. PubMed ID: 10023703
[TBL] [Abstract][Full Text] [Related]
4. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar).
Advani R; Saba HI; Tallman MS; Rowe JM; Wiernik PH; Ramek J; Dugan K; Lum B; Villena J; Davis E; Paietta E; Litchman M; Sikic BI; Greenberg PL
Blood; 1999 Feb; 93(3):787-95. PubMed ID: 9920827
[TBL] [Abstract][Full Text] [Related]
5. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
Narayan R; Blonquist TM; Emadi A; Hasserjian RP; Burke M; Lescinskas C; Neuberg DS; Brunner AM; Hobbs G; Hock H; McAfee SL; Chen YB; Attar E; Graubert TA; Bertoli C; Moran JA; Bergeron MK; Foster JE; Ramos AY; Som TT; Vartanian MK; Story JL; McGregor K; Macrae M; Behnan T; Wey MC; Rae J; Preffer FI; Lesho P; Duong VH; Mann ML; Ballen KK; Connolly C; Amrein PC; Fathi AT
Cancer; 2020 Mar; 126(6):1264-1273. PubMed ID: 31860140
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II study of clofarabine, etoposide, and mitoxantrone in patients with refractory or relapsed acute leukemia.
Abbi KK; Rybka W; Ehmann WC; Claxton DF
Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):41-6. PubMed ID: 25085441
[TBL] [Abstract][Full Text] [Related]
7. Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia.
Visani G; Milligan D; Leoni F; Chang J; Kelsey S; Marcus R; Powles R; Schey S; Covelli A; Isidori A; Litchman M; Piccaluga PP; Mayer H; Malagola M; Pfister C
Leukemia; 2001 May; 15(5):764-71. PubMed ID: 11368437
[TBL] [Abstract][Full Text] [Related]
8. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
[TBL] [Abstract][Full Text] [Related]
9. Mitoxantrone and etoposide in patients with relapsed and refractory acute nonlymphocytic leukemia.
Rowe JM; Mazza JJ; Hines JD; Cassileth PA; Oken MM; Bennett JM; Andersen J
Haematol Blood Transfus; 1990; 33():326-9. PubMed ID: 2182427
[No Abstract] [Full Text] [Related]
10. Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.
O'Brien MM; Lacayo NJ; Lum BL; Kshirsagar S; Buck S; Ravindranath Y; Bernstein M; Weinstein H; Chang MN; Arceci RJ; Sikic BI; Dahl GV
Pediatr Blood Cancer; 2010 May; 54(5):694-702. PubMed ID: 20209646
[TBL] [Abstract][Full Text] [Related]
11. Gemtuzumab ozogamicin, mitoxantrone, and etoposide in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy.
Boyiadzis M; Redner RL; Raptis A; Hou JZ; Agha M; Foon KA
Ann Hematol; 2011 Jun; 90(6):733-5. PubMed ID: 20857113
[No Abstract] [Full Text] [Related]
12. Mitoxantrone, etoposide and cytarabine in the treatment of acute nonlymphocytic leukemia.
Björkholm M; Björnsdottir J; Stenke L; Grimfors G
Oncology; 1990; 47(2):112-4. PubMed ID: 2314823
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia.
Kornblau SM; Estey E; Madden T; Tran HT; Zhao S; Consoli U; Snell V; Sanchez-Williams G; Kantarjian H; Keating M; Newman RA; Andreeff M
J Clin Oncol; 1997 May; 15(5):1796-802. PubMed ID: 9164187
[TBL] [Abstract][Full Text] [Related]
14. Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.
Halpern AB; Othus M; Huebner EM; Buckley SA; Pogosova-Agadjanyan EL; Orlowski KF; Scott BL; Becker PS; Hendrie PC; Chen TL; Percival MM; Estey EH; Stirewalt DL; Walter RB
Leukemia; 2017 Dec; 31(12):2560-2567. PubMed ID: 28555084
[TBL] [Abstract][Full Text] [Related]
15. Treatment of relapsed and refractory acute myeloid leukemia in adults.
Lazzarino M; Morra E; Alessandrino EP; Merante S; Bernasconi P; Bonfichi M; Caldera D; Bernasconi C
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():121-3. PubMed ID: 2653487
[No Abstract] [Full Text] [Related]
16. Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia.
Yamamoto C; Ito S; Mashima K; Umino K; Minakata D; Yamasaki R; Kawasaki Y; Sugimoto M; Nakano H; Ashizawa M; Okazuka K; Hatano K; Sato K; Oh I; Fujiwara S; Ohmine K; Suzuki T; Muroi K; Kanda Y
Leuk Lymphoma; 2016 Nov; 57(11):2541-7. PubMed ID: 26917050
[TBL] [Abstract][Full Text] [Related]
17. Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: a randomised phase II trial from HOVON, the Dutch-Belgian Haemato-Oncology Working Group for adults.
Daenen S; van der Holt B; Verhoef GE; Löwenberg B; Wijermans PW; Huijgens PC; van Marwijk Kooy R; Schouten HC; Kramer MH; Ferrant A; van den Berg E; Steijaert MM; Verdonck LF; Sonneveld P
Leuk Res; 2004 Oct; 28(10):1057-67. PubMed ID: 15289018
[TBL] [Abstract][Full Text] [Related]
18. Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia.
Lee SS; Lee JH; Lee JH; Kim DY; Kim SH; Lim SN; Lee YS; Seol M; Ryu SG; Kang YA; Jang S; Park CJ; Chi HS; Yun SC; Lee KH
Leuk Res; 2009 Apr; 33(4):511-7. PubMed ID: 18819710
[TBL] [Abstract][Full Text] [Related]
19. Mitoxantrone and etoposide: an effective regimen for refractory or relapsed acute myelogenous leukemia.
Lazzarino M; Morra E; Alessandrino EP; Orlandi E; Pagnucco G; Merante S; Bernasconi P; Inverardi D; Bonfichi M; Bernasconi C
Eur J Haematol; 1989 Nov; 43(5):411-6. PubMed ID: 2612614
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with mitoxantrone and etoposide in adult acute myelogenous leukemia.
Knauf WU; Ho AD; Körbling M; Hunstein W
Haematol Blood Transfus; 1990; 33():314-5. PubMed ID: 1969834
[No Abstract] [Full Text] [Related]
[Next] [New Search]
